Nashville-based eye care pharmaceutical company Harrow Inc. reported mixed results for the third quarter on Monday, with earnings that beat analysts' expectations and revenue that fell short of estimates. 

Mark Baum

Mark Baum 

Harrow, which also gave an update on its recent agreement to acquire Melt Pharmaceuticals Inc. (read here), reported Q3 earnings per share of $0.30, $0.09 better than analysts' estimate of $0.24.

Tags

Recommended for you